Synageva BioPharma starts rolling submission of a BLA to FDA
Synageva announced the start of a rolling submission of a Biologics License Application to the FDA for sebelipase alfa as treatment for patients with lysosomal acid lipase deficiency, a rare genetic disease with significant morbidity and early mortality. October 21, 2014